576 related articles for article (PubMed ID: 25072261)
1. Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers.
Golan T; Kanji ZS; Epelbaum R; Devaud N; Dagan E; Holter S; Aderka D; Paluch-Shimon S; Kaufman B; Gershoni-Baruch R; Hedley D; Moore MJ; Friedman E; Gallinger S
Br J Cancer; 2014 Sep; 111(6):1132-8. PubMed ID: 25072261
[TBL] [Abstract][Full Text] [Related]
2. Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer.
Golan T; Sella T; O'Reilly EM; Katz MH; Epelbaum R; Kelsen DP; Borgida A; Maynard H; Kindler H; Friedmen E; Javle M; Gallinger S
Br J Cancer; 2017 Mar; 116(6):697-702. PubMed ID: 28183138
[TBL] [Abstract][Full Text] [Related]
3. Should platinum-based chemotherapy be preferred for germline BReast CAncer genes (BRCA) 1 and 2-mutated pancreatic ductal adenocarcinoma (PDAC) patients? A systematic review and meta-analysis.
Rebelatto TF; Falavigna M; Pozzari M; Spada F; Cella CA; Laffi A; Pellicori S; Fazio N
Cancer Treat Rev; 2019 Nov; 80():101895. PubMed ID: 31542591
[TBL] [Abstract][Full Text] [Related]
4. Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation.
Wattenberg MM; Asch D; Yu S; O'Dwyer PJ; Domchek SM; Nathanson KL; Rosen MA; Beatty GL; Siegelman ES; Reiss KA
Br J Cancer; 2020 Feb; 122(3):333-339. PubMed ID: 31787751
[TBL] [Abstract][Full Text] [Related]
5. BRCA1/BRCA2 Germline Mutation Carriers and Sporadic Pancreatic Ductal Adenocarcinoma.
Blair AB; Groot VP; Gemenetzis G; Wei J; Cameron JL; Weiss MJ; Goggins M; Wolfgang CL; Yu J; He J
J Am Coll Surg; 2018 Apr; 226(4):630-637.e1. PubMed ID: 29309945
[TBL] [Abstract][Full Text] [Related]
6. Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma.
O'Reilly EM; Lee JW; Lowery MA; Capanu M; Stadler ZK; Moore MJ; Dhani N; Kindler HL; Estrella H; Maynard H; Golan T; Segal A; Salo-Mullen EE; Yu KH; Epstein AS; Segal M; Brenner R; Do RK; Chen AP; Tang LH; Kelsen DP
Cancer; 2018 Apr; 124(7):1374-1382. PubMed ID: 29338080
[TBL] [Abstract][Full Text] [Related]
7. Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma.
Golan T; O'Kane GM; Denroche RE; Raitses-Gurevich M; Grant RC; Holter S; Wang Y; Zhang A; Jang GH; Stossel C; Atias D; Halperin S; Berger R; Glick Y; Park JP; Cuggia A; Williamson L; Wong HL; Schaeffer DF; Renouf DJ; Borgida A; Dodd A; Wilson JM; Fischer SE; Notta F; Knox JJ; Zogopoulos G; Gallinger S
Gastroenterology; 2021 May; 160(6):2119-2132.e9. PubMed ID: 33524400
[TBL] [Abstract][Full Text] [Related]
8. Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma.
Holter S; Borgida A; Dodd A; Grant R; Semotiuk K; Hedley D; Dhani N; Narod S; Akbari M; Moore M; Gallinger S
J Clin Oncol; 2015 Oct; 33(28):3124-9. PubMed ID: 25940717
[TBL] [Abstract][Full Text] [Related]
9. Pancreas cancer and BRCA: A critical subset of patients with improving therapeutic outcomes.
Momtaz P; O'Connor CA; Chou JF; Capanu M; Park W; Bandlamudi C; Berger MF; Kelsen DP; Suehnholz SP; Chakravarty D; Yu KH; Varghese AM; Zervoudakis A; Li J; Ku GY; Park JS; Shcherba M; Harding JJ; Goldberg Z; Abou-Alfa GK; Salo-Mullen EE; Stadler ZK; Iacobuzio-Donahue CA; O'Reilly EM
Cancer; 2021 Dec; 127(23):4393-4402. PubMed ID: 34351646
[TBL] [Abstract][Full Text] [Related]
10. Brain Metastases in Pancreatic Ductal Adenocarcinoma: Assessment of Molecular Genotype-Phenotype Features-An Entity With an Increasing Incidence?
Jordan EJ; Lowery MA; Basturk O; Allen PJ; Yu KH; Tabar V; Beal K; Reidy DL; Yamada Y; Janjigian Y; Abou-Alfa GK; O'Reilly EM
Clin Colorectal Cancer; 2018 Jun; 17(2):e315-e321. PubMed ID: 29496399
[TBL] [Abstract][Full Text] [Related]
11. BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer.
Pishvaian MJ; Biankin AV; Bailey P; Chang DK; Laheru D; Wolfgang CL; Brody JR
Br J Cancer; 2017 Apr; 116(8):1021-1026. PubMed ID: 28291774
[TBL] [Abstract][Full Text] [Related]
12. BRCA-mutant pancreatic ductal adenocarcinoma.
Lai E; Ziranu P; Spanu D; Dubois M; Pretta A; Tolu S; Camera S; Liscia N; Mariani S; Persano M; Migliari M; Donisi C; Demurtas L; Pusceddu V; Puzzoni M; Scartozzi M
Br J Cancer; 2021 Nov; 125(10):1321-1332. PubMed ID: 34262146
[TBL] [Abstract][Full Text] [Related]
13. Maintenance Therapy for ATM-Deficient Pancreatic Cancer by Multiple DNA Damage Response Interferences after Platinum-Based Chemotherapy.
Roger E; Gout J; Arnold F; Beutel AK; Müller M; Abaei A; Barth TFE; Rasche V; Seufferlein T; Perkhofer L; Kleger A
Cells; 2020 Sep; 9(9):. PubMed ID: 32948057
[TBL] [Abstract][Full Text] [Related]
14. The role of PARP inhibitors in germline BRCA-associated pancreatic ductal adenocarcinoma.
Moffat GT; O'Reilly EM
Clin Adv Hematol Oncol; 2020 Mar; 18(3):168-179. PubMed ID: 32609666
[TBL] [Abstract][Full Text] [Related]
15. EUS-based Pancreatic Cancer Surveillance in
Katona BW; Long JM; Ahmad NA; Attalla S; Bradbury AR; Carpenter EL; Clark DF; Constantino G; Das KK; Domchek SM; Dudzik C; Ebrahimzadeh J; Ginsberg GG; Heiman J; Kochman ML; Maxwell KN; McKenna DB; Powers J; Shah PD; Wangensteen KJ; Rustgi AK
Cancer Prev Res (Phila); 2021 Nov; 14(11):1033-1040. PubMed ID: 34341011
[TBL] [Abstract][Full Text] [Related]
16. Germline mutations of homologous recombination genes and clinical outcomes in pancreatic cancer: a multicenter study in Taiwan.
Cheng SM; Su YY; Chiang NJ; Wang CJ; Chao YJ; Huang CJ; Tsai HJ; Chen SH; Chang CY; Tsai CR; Li YJ; Yen CJ; Chuang SC; Chang JS; Shan YS; Hwang DY; Chen LT
J Biomed Sci; 2024 Feb; 31(1):21. PubMed ID: 38350919
[TBL] [Abstract][Full Text] [Related]
17. Risk of pancreatic ductal adenocarcinoma associated with carriage of BRCA1 and/or BRCA2 mutation: A systematic review and meta-analysis.
McGarry JL; Creavin B; Kelly ME; Gallagher TK
J Surg Oncol; 2022 Nov; 126(6):1028-1037. PubMed ID: 35770919
[TBL] [Abstract][Full Text] [Related]
18. Biologic behavior of resected BRCA-mutated pancreatic cancer: Comparison with sporadic pancreatic cancer and other BRCA-related cancers.
Kim SH; Hwang HK; Lee WJ; Kang CM
Pancreatology; 2021 Apr; 21(3):544-549. PubMed ID: 33612442
[TBL] [Abstract][Full Text] [Related]
19. BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts.
Lohse I; Borgida A; Cao P; Cheung M; Pintilie M; Bianco T; Holter S; Ibrahimov E; Kumareswaran R; Bristow RG; Tsao MS; Gallinger S; Hedley DW
Br J Cancer; 2015 Jul; 113(3):425-32. PubMed ID: 26180923
[TBL] [Abstract][Full Text] [Related]
20. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study.
Labori KJ; Katz MH; Tzeng CW; Bjørnbeth BA; Cvancarova M; Edwin B; Kure EH; Eide TJ; Dueland S; Buanes T; Gladhaug IP
Acta Oncol; 2016; 55(3):265-77. PubMed ID: 26213211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
